東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Health technology assessment of thio...

Donnan, Jennifer Renee.

Linked to FindBook

Google Book

Amazon

博客來

Health technology assessment of thiopurine methyltransferase testing for guiding 6-mercaptopurine doses in pediatric patients with acute lymphoblastic leukemia.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Health technology assessment of thiopurine methyltransferase testing for guiding 6-mercaptopurine doses in pediatric patients with acute lymphoblastic leukemia./
Author:	Donnan, Jennifer Renee.
Description:	144 p.
Notes:	Source: Masters Abstracts International, Volume: 48-04, page: 2220.
Contained By:	Masters Abstracts International48-04.
Subject:	Health Sciences, Medicine and Surgery. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=MR59355
ISBN:	9780494593554

Health technology assessment of thiopurine methyltransferase testing for guiding 6-mercaptopurine doses in pediatric patients with acute lymphoblastic leukemia.
Donnan, Jennifer Renee.

Health technology assessment of thiopurine methyltransferase testing for guiding 6-mercaptopurine doses in pediatric patients with acute lymphoblastic leukemia. - 144 p.

Source: Masters Abstracts International, Volume: 48-04, page: 2220.

Thesis (M.Sc.)--University of Toronto (Canada), 2009.

This study determined whether phenotype or genotype tests for thiopurine methyltransferase (TPMT) are cost effective interventions for guiding doses of 6-mercaptopurine in children with acute lymphoblastic leukemia (ALL) compared to standard weight-based dosing. A systematic review of the literature was conducted to assess the accuracy of the TPMT technologies, followed by a cost effectiveness analysis which compared genotype, phenotype and weight-based dosing strategies over a three month time horizon. Both TPMT phenotype and genotype technologies were considered accurate though there is no gold standard. Additionally, included studies were of low methodological quality. Neither of the interventions showed a benefit in survival and both were more costly compared to standard weight-based dosing. At this time there is insufficient evidence to recommend the use of phenotype or genotype testing prior to 6-mercaptopurine therapy to guide initial doses in pediatric ALL patients.

ISBN: 9780494593554Subjects--Topical Terms:

1017756
Health Sciences, Medicine and Surgery.

Health technology assessment of thiopurine methyltransferase testing for guiding 6-mercaptopurine doses in pediatric patients with acute lymphoblastic leukemia.
LDR:01860nam 2200253 4500 001 1403606
005 20111118100018.5
008 130515s2009 ||||||||||||||||| ||eng d
020 $a 9780494593554
035 $a (UMI)AAIMR59355
035 $a AAIMR59355
040 $a UMI $c UMI
100 1 $a Donnan, Jennifer Renee. $3 1682881
245 1 0 $a Health technology assessment of thiopurine methyltransferase testing for guiding 6-mercaptopurine doses in pediatric patients with acute lymphoblastic leukemia.
300 $a 144 p.
500 $a Source: Masters Abstracts International, Volume: 48-04, page: 2220.
502 $a Thesis (M.Sc.)--University of Toronto (Canada), 2009.
520 $a This study determined whether phenotype or genotype tests for thiopurine methyltransferase (TPMT) are cost effective interventions for guiding doses of 6-mercaptopurine in children with acute lymphoblastic leukemia (ALL) compared to standard weight-based dosing. A systematic review of the literature was conducted to assess the accuracy of the TPMT technologies, followed by a cost effectiveness analysis which compared genotype, phenotype and weight-based dosing strategies over a three month time horizon. Both TPMT phenotype and genotype technologies were considered accurate though there is no gold standard. Additionally, included studies were of low methodological quality. Neither of the interventions showed a benefit in survival and both were more costly compared to standard weight-based dosing. At this time there is insufficient evidence to recommend the use of phenotype or genotype testing prior to 6-mercaptopurine therapy to guide initial doses in pediatric ALL patients.
590 $a School code: 0779.
650 4 $a Health Sciences, Medicine and Surgery. $3 1017756
650 4 $a Health Sciences, Oncology. $3 1018566
690 $a 0564
690 $a 0992
710 2 $a University of Toronto (Canada). $3 1017674
773 0 $t Masters Abstracts International $g 48-04.
790 $a 0779
791 $a M.Sc.
792 $a 2009
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=MR59355